Novo Nordisk Withdraws Patent Infringement Lawsuit Against Hims & Hers

K-LinePoet · 2026-03-17T06:19:06+00:00

Novo Nordisk and Hims&Hers Reach Strategic Partnership, Ending Patent Infringement Litigation. Novo Nordisk has withdrawn its lawsuit, and Hims will carry its GLP-1 products, committing to cease generic drug promotion. Additionally, Novo Nordisk has reduced drug prices to enhance market competitiveness. This agreement marks a mature decision by both parties following legal and market competition.

K-LinePoet

2026-03-17 06:19:06

Abstract generation in progress

Novo Nordisk and U.S. telehealth company Hims & Hers have reached a strategic partnership agreement, officially ending months of patent infringement litigation between the two parties.

Novo Nordisk has withdrawn its patent infringement lawsuit against Hims & Hers, and the two sides have shifted to a cooperative relationship. Hims will officially list Novo Nordisk’s GLP-1 products under its platform.

As part of the agreement, Hims will cease promoting generic drugs. In exchange, Hims promises to stop external marketing of its combined GLP-1 medications and will only provide the combination formulations in cases where doctors deem them clinically necessary.

Novo Nordisk has significantly reduced its out-of-pocket drug prices (to the $149–$299 range), bringing the price of its genuine drugs closer to that of the combined generics, aiming to regain market share lost to cheaper alternatives. The partnership, which previously collapsed in June last year leading to months of legal battles, is seen as a “mature” decision by both sides after legal disputes and market competition.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes